Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NUWE 
Nuwellis Inc (NUWE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: NUWE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.81% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.11M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 0.11 | 52 Weeks Range 3.09 - 175.98 | Updated Date 10/19/2025 |
52 Weeks Range 3.09 - 175.98 | Updated Date 10/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -313.92 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -176.45% | Operating Margin (TTM) -168.46% |
Management Effectiveness
Return on Assets (TTM) -79.07% | Return on Equity (TTM) -440.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1010153 | Price to Sales(TTM) 0.37 |
Enterprise Value -1010153 | Price to Sales(TTM) 0.37 | ||
Enterprise Value to Revenue 0.22 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 902665 | Shares Floating 876136 |
Shares Outstanding 902665 | Shares Floating 876136 | ||
Percent Insiders 2.92 | Percent Institutions 1.49 |
Upturn AI SWOT
Nuwellis Inc
Company Overview
History and Background
Nuwellis Inc. (formerly CHF Solutions) was founded in 2006. It focuses on developing, manufacturing, and commercializing medical devices for fluid management in critical care settings. The company initially focused on treating fluid overload in patients with heart failure but has expanded its focus to other conditions.
Core Business Areas
- Acute Care: This segment focuses on providing products and services to hospitals and acute care facilities for managing fluid overload in patients. The Aquadex FlexFlow system is the primary product in this segment.
- Pediatric Care: This segment focuses on providing products for fluid management in pediatric patients, particularly in critical care settings.
Leadership and Structure
The company has a CEO who leads the executive team. The organizational structure is typical for a small medical device company, with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Aquadex FlexFlow System: The Aquadex FlexFlow system is Nuwellis's primary product. It is a simplified ultrafiltration system designed to remove excess fluid from patients suffering from fluid overload. Precise market share data is difficult to ascertain, but adoption is growing in targeted hospital segments. Competitors include companies offering diuretics and other fluid management therapies. Revenue is largely based on disposables associated with the machine's use, with some revenue from the sale of the device itself. Competitors include Baxter International (BAX) and Fresenius Medical Care (FMS) for related fluid management solutions.
Market Dynamics
Industry Overview
The market for fluid management solutions is growing due to the increasing prevalence of conditions like heart failure and acute kidney injury. The aging population and advancements in medical technology also contribute to market growth.
Positioning
Nuwellis is positioned as a provider of specialized ultrafiltration therapy, targeting patients with fluid overload who may not respond well to traditional diuretics. Their competitive advantage lies in the Aquadex system's ease of use and effectiveness in removing excess fluid.
Total Addressable Market (TAM)
The TAM for fluid overload management is estimated to be in the billions of dollars, encompassing hospital stays, medication, and other therapies. Nuwellis is positioned to capture a portion of this market by offering a specialized ultrafiltration solution.
Upturn SWOT Analysis
Strengths
- Specialized ultrafiltration technology
- Focus on a niche market (fluid overload)
- Aquadex system's ease of use
- Potential for growth in pediatric care
Weaknesses
- Limited product portfolio
- Relatively small market capitalization
- Dependence on a single key product
- Limited marketing and sales resources compared to larger competitors
Opportunities
- Expanding into new markets (e.g., home healthcare)
- Developing new applications for ultrafiltration technology
- Partnerships with hospitals and healthcare systems
- Increasing awareness of ultrafiltration therapy among physicians
Threats
- Competition from established medical device companies
- Changes in reimbursement policies
- Technological advancements that could render their product obsolete
- Clinical trials of competitors may lead to more acceptance of other products
- Regulatory hurdles and approval processes
Competitors and Market Share
Key Competitors
- BAX
- FMS
Competitive Landscape
Nuwellis competes with larger medical device companies that offer alternative fluid management solutions. Nuwellis' advantage lies in its specialized ultrafiltration technology, but it faces challenges in terms of market reach and resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, reflecting the challenges of commercializing a novel medical device. Growth rates have varied depending on the adoption of the Aquadex system and reimbursement dynamics.
Future Projections: Future growth depends on continued adoption of the Aquadex system, expansion into new markets, and successful execution of their business strategy. Analyst estimates suggest potential for revenue growth in the coming years, contingent upon market acceptance and competition.
Recent Initiatives: Recent initiatives include expanding their sales force, targeting specific hospital departments, and exploring partnerships to increase market access.
Summary
Nuwellis Inc. is a small medical device company focused on fluid management via ultrafiltration. Their Aquadex system targets a niche market within fluid overload treatment. The company is growing but faces stiff competition from larger, established players. Overall, the company is highly speculative with significant opportunity but also high risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news sources
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share estimates are approximate. Always consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuwellis Inc
Exchange NASDAQ | Headquaters Eden Prairie, MN, United States | ||
IPO Launch date 2012-02-16 | CEO, President & Chairman of the Board Mr. John L. Erb | ||
Sector Healthcare | Industry Medical Devices | Full time employees 38 | Website https://www.nuwellis.com |
Full time employees 38 | Website https://www.nuwellis.com | ||
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.